Intellia Therapeutics Faces Severe Setback Following Clinical Trial Death
Published on 11/14/2025 at 05:21 | Redaktion boerse-global.de
Intellia Therapeutics shares are experiencing a dramatic downturn after a patient death in a pivotal clinical study triggered multiple analyst downgrades and eroded investor confidence. The future of the company’s leading therapeutic candidate now hangs in the balance.
The financial markets delivered a swift and severe verdict. Intellia’s stock value plummeted significantly over the past week as a direct consequence of the negative developments. Several prominent financial institutions, including JPMorgan, Evercore ISI, and Jones Trading, responded by downgrading their ratings on the stock and substantially reducing their price targets. The profound uncertainty surrounding the company’s most advanced drug candidate has placed the equity firmly in a downward trajectory.
Clinical Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
